Atrium Therapeutics (RNA) investor relations material

Executive summary

• Focused on RNA therapeutics for cardiomyopathies, leveraging a proprietary delivery platform targeting genetic cardiac diseases.

• Pipeline includes ATR 1072 for PRKAG2 syndrome, ATR 1086 for PLN cardiomyopathy, and two additional undisclosed programs.

• Achieved FDA and Health Canada clearance for IND application of ATR 1072 and launched the Corventis Phase 1/2 trial targeting PRKAG2 syndrome.

• Became an independent public company in February 2026 following a spin-off from Avidity Biosciences after its acquisition by Novartis.

• Earned a $15 million milestone payment from Bristol Myers Squibb under a global cardiovascular collaboration.

Financial highlights

• Collaboration revenue was $3.0M for Q2 2026, down from $3.8M in Q2 2025; $22.6M for H1 2026, up from $5.4M in H1 2025 due to a $15M BMS milestone.

• Net loss was $20.2M for Q2 2026 (vs. $12.9M in Q2 2025) and $36.8M for H1 2026 (vs. $20.3M in H1 2025).

• Research and development expenses rose to $15.3M in Q2 2026 (from $13.3M) and $32.0M in H1 2026 (from $20.2M).

• General and administrative expenses increased to $10.3M in Q2 2026 (from $3.4M) and $30.5M in H1 2026 (from $5.5M).

• Cash, cash equivalents, and short-term investments totaled $263.9M as of June 30, 2026.

Outlook and guidance

• Existing cash and investments expected to fund operations for at least 12 months from the filing date, with some guidance indicating runway through mid-2028 including the BMS milestone payment.

• First participant enrollment in Corventis Phase 1/2 trial expected by end of 2026; initial proof-of-concept data anticipated in H2 2027.

• IND application for ATR 1086 planned for 2027, with IND-enabling studies starting in 2026.

• Anticipates increased R&D and G&A expenses as pipeline advances and public company infrastructure expands.

• Plans to finance future needs through equity, debt, or strategic collaborations.